Syndexa and Technology Transfer at Harvard University

Richard G. Hamermesh; David  Kiron

Case | HBS Case Collection | September 2007 (Revised May 2009)

Syndexa and Technology Transfer at Harvard University

Abstract

Gokhan Hotamisligil is a star researcher at Harvard School of Public Health who has made groundbreaking discoveries linking fat cells, inflammation, and diabetes. He now wants to form a company to commercialize these discoveries. At the same time, Isaac Kohlberg, the head of Harvard's Office of Technology Development (OTD), is eager to improve Harvard's record in commercializing science. Describes the negotiations between Hotamisligil, OTD, the new company, and the School of Public Health to establish appropriate licensing and sponsored research agreements.

Keywords: Business Startups; Higher Education; Entrepreneurship; Innovation and Invention; Intellectual Property; Rights; Agreements and Arrangements; Science-Based Business; Commercialization; Biotechnology Industry; Health Industry;

Format: Print

19 pages

Educators Purchase

Citation:

Hamermesh, Richard G., and David Kiron. "Syndexa and Technology Transfer at Harvard University." Harvard Business School Case 808-073, September 2007. (Revised May 2009.)

The case is set in March 2019, and tells the story of the founding of the Dementia Discovery Fund (DDF). The idea for the fund began in 2015, when then-Prime Minister David Cameron spoke about the importance of making breakthroughs in dementia research, and pledged money from the UK government for research. This in turn led to the search for a venture capital (VC) firm that could lead manage a fund, and the selection of SV Health to do that, including having Kate Bingham as a managing partner. The case describes the social and scientific needs for more dementia research, as well as the fundraising and initial team building of the fund. After the fund grows beyond the expected size, the case describes the hiring of a CEO, and asks what the next investment for the fund should be: a start-up that might soon be able to launch clinical trials, or an early-stage company with promising new research?

It is early 2018, and Emily Park, managing director of impact for the Abreu Family Office, is meeting the next day with Tomás and Maria Abreu to discuss the various ways in which the Abreus can allocate a planned $100 million to make a meaningful difference in cancer patients’ lives. Park has spent the past few months working on this project and has uncovered a multitude of options, from supporting high-performing disease-focused organizations through venture philanthropy; to investing in a fund or directly into ventures and possibly earning a good return on investment in the process; to helping address system-wide issues such as the better organization and funding of clinical trials. As she prepares to present her findings to the Abreus, she wonders which one(s) will spark their interest as the way to have the most meaningful impact, and what implications their ultimate decision will have on the Family Office in terms of its capital outlays, structure, staffing, and many other categories.

Faculty & Research

Syndexa and Technology Transfer at Harvard University

Abstract

Citation:

About the Author

More from the Author